Neuronetics Joins Neuropsychiatric Drug Commercialization Panel at B. Riley Summit
Event summary
- Neuronetics to participate in panel on commercializing neuropsychiatric drugs at B. Riley's Mind, Muscle & Vision Summit on July 16, 2026.
- Panel titled 'Commercializing the Next Wave of Novel Neuropsychiatric Drugs' alongside Compass Pathways.
- Event is invitation-only and in-person at InterContinental Boston; no live webcast available.
- Management will also hold one-on-one meetings with institutional investors during the day.
The big picture
Neuronetics' participation underscores the growing emphasis on commercializing innovative neuropsychiatric treatments beyond traditional pharmaceuticals. The event provides a platform for Neuronetics to highlight its dual approach of combining NeuroStar TMS technology with direct patient care through Greenbrook clinics, positioning itself as a key player in interventional mental health.
What we're watching
- Competitive Positioning
- How Neuronetics' participation alongside Compass Pathways will shape its narrative in the neuropsychiatric drug commercialization space.
- Investor Sentiment
- The impact of one-on-one meetings on institutional investor perception of Neuronetics' growth strategy.
- Market Differentiation
- Whether the company can leverage its NeuroStar and Greenbrook assets to stand out in a crowded neuropsychiatric treatment landscape.
Related topics